Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Illinois Business Review.
Press releases published on June 15, 2025
CAR FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 24 Deadline in Securities Class Action - CAR
GlobeNewswire
·
June 15, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class …
CAR 截止日期提醒：廣受信賴的投資人法律顧問 ROSEN 鼓勵損失超過 10 萬美元的 Avis Budget Group, Inc 投資人於 6 月 24 日證券集體訴訟重要截止日期前聘請律師 - CAR
GlobeNewswire
·
June 15, 2025
紐約, June 15, 2025 (GLOBE NEWSWIRE) -- 事由：全球投資人權益律師事務所 Rosen Law Firm 提醒在 2024 年 2 月 16 日至 2025 年 2 月 10 日（含首尾兩天，簡稱「集體訴訟期間」）期間購買 Avis Budget Group, Inc. (NASDAQ: CAR) 股票的人士，2025 年 6 月 24 日是重要的首席原告截止日期。 影響性：倘若您在集體訴訟期內曾購買 Avis Budget …
XRP Ledger Payment Volume Skyrockets Over 1,000%, Analysts Expect Similar For Remittix (RTX)
GlobeNewswire
·
June 15, 2025
New York, June 15, 2025 (GLOBE NEWSWIRE) -- Surprises are common in the crypto sphere but an unprecedented 1,000% surge in XRP Ledger’s payment volume hits different. It speaks of marvelous things to come. That’s why investors are scrambling to position …
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
GlobeNewswire
·
June 15, 2025
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent …
Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …
GlobeNewswire
·
June 15, 2025
EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe …
Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence – Hagens Berman
GlobeNewswire
·
June 15, 2025
SAN FRANCISCO, June 15, 2025 (GLOBE NEWSWIRE) -- Shares in Napco Security Technologies, Inc. (NASDAQ: NSSC) are trading down nearly 21% year-to-date, as the security technology company continues to face heightened scrutiny as it navigates both legal and …
IBTA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Ibotta, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – IBTA
GlobeNewswire
·
June 15, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc. (NYSE: IBTA): (1) pursuant and/or traceable to the registration statement and related prospectus ( …
IBTA 最終截止日期：享譽全球的律師事務所 ROSEN 鼓勵損失超過 10 萬美元的 Ibotta, Inc. 投資者在該事務所對 IBTA 首次提出證券集體訴訟之重要截止日期 6 月 16 日前聘請律師
GlobeNewswire
·
June 15, 2025
紐約, June 15, 2025 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 提醒：(1) 根據及／或可追溯至因 Ibotta, Inc.（NYSE: IBTA）於 2024 年 4 月 18 日進行首次公開招股（簡稱「IPO」）所發行之註冊聲明及相關招股章程（統稱「註冊聲明」）而購買該公司證券之人士；或 (2) 於 2024 年 4 月 18 日至 2025 年 2 月 26 …
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
GlobeNewswire
·
June 15, 2025
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, …
WST IMPORTANT DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – WST
GlobeNewswire
·
June 15, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive ( …
WST 重要截止日期：全美審訊法律顧問 ROSEN 鼓勵損失 10 萬美元以上的 West Pharmaceutical Services, Inc. 投資者在對 WST 提出證券集體訴訟的重要截止日期前聘請律師
GlobeNewswire
·
June 15, 2025
紐約, June 15, 2025 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 提醒在 2023 年 2 月 16 日至 2025 年 2 月 12 日（包括首尾兩日，下稱「集體訴訟期」）期間購買了 West Pharmaceutical Services, Inc. (NYSE: WST) 普通股之人士注意，重要的首席原告截止日期為 2025 年 7 月 7 日。 影響：如果您在集體訴訟期間購買 West …
Reputation Pros Named Best Online Reputation Management Company of 2025 by Modern Luxury Magazine
GlobeNewswire
·
June 15, 2025
Miami, FL, June 15, 2025 (GLOBE NEWSWIRE) -- Modern Luxury Magazine today announced Reputation Pros as the best online reputation management company of 2025 in its annual Best Online Reputation Management Companies feature, published online in May 2025. …
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NWTN Inc. - NWTN
GlobeNewswire
·
June 15, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NWTN Inc. (“NWTN” or the “Company”) (NASDAQ: NWTN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, …
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
GlobeNewswire
·
June 15, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com …
Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG
GlobeNewswire
·
June 15, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and certain officers. The class action, filed in the United States District …
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
GlobeNewswire
·
June 15, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. (“Zeo” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581- …
Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers – FTRE
GlobeNewswire
·
June 15, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fortrea Holdings, Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) and certain officers. The class action, filed in the United States …
Pomerantz Law Firm Announces the Filing of a Class Action Against Red Cat Holdings, Inc. and Certain Officers – RCAT
GlobeNewswire
·
June 15, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Red Cat Holdings, Inc. (“Red Cat” or the “Company”) (NASDAQ: RCAT) and certain officers. The class action, filed in the United States …
Pomerantz Law Firm Announces the Filing of a Class Action Against Bitfarms Ltd. and Certain Officers – BITF
GlobeNewswire
·
June 15, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Bitfarms Ltd. ("Bitfarms" or the "Company") (NASDAQ: BITF) and certain officers. The class action, filed in the United States District …
Pomerantz Law Firm Announces the Filing of a Class Action Against MicroStrategy Incorporated d/b/a Strategy and Certain Officers – MSTR
GlobeNewswire
·
June 15, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy (“Strategy” or the “Company”) (NASDAQ: MSTR) and certain officers. The class action, filed in …